{
  "id": 6825103,
  "title": "Intuitive surgical EVP Mark Brosius sells $17,140 in stock",
  "url": "https://urgent.news/2026/09/11/intuitive-surgical-evp-mark-brosius-sells-17-140-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-11T23:45:54.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/intuitive-surgical-evp-mark-brosius-sells-17140-in-stock-93CH-4898564"
  },
  "original_language": "en",
  "account": "Intuitive Surgical's Executive Vice President and Chief Manufacturing and Supply Chain Officer, Mark Brosius, sold a total of $17,140 worth of company stock in two transactions during September 2026. The first sale involved 23 shares at $347.66 per share on September 10, 2026, while the second transaction comprised 25 shares at $365.79 each on September 11, 2026. These sales were executed according to a pre-determined Rule 10b5-1 trading plan, which is scheduled to conclude on February 14, 2027. As a result of these transactions, Brosius currently owns 764 shares of Intuitive Surgical common stock. Despite the stock's current price of $369.15, which represents a 34.8% decrease year-to-date, the company's financial performance remains robust. Intuitive Surgical's second-quarter sales surged by 19% to $2.89 billion, exceeding analysts' expectations. The company's various segments, including instruments and accessories (up 18% to $1.73 billion), systems (up 19% to $685 million), and services (up 21% to $472 million), all contributed to this growth. Additionally, earnings per share increased by 28% to $2.80, surpassing analyst forecasts by 12%. In response to these developments, several financial analysts have revised their ratings and price targets for Intuitive Surgical. Oppenheimer upgraded the stock to \"Outperform,\" setting a price target of $500, while UBS initiated coverage with a \"Buy\" rating and a similar target of $500. Conversely, Bernstein maintained an \"Outperform\" rating but reduced its price target to $685 due to concerns regarding U.S. growth prospects. Piper Sandler, on the other hand, retained an \"Overweight\" rating with a $470 price target, expressing confidence in the company's future.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Qualcomm EVP, CFO & COO Palkhiwala sells $457,129 in QCOM stock",
        "url": "https://urgent.news/2026/09/11/qualcomm-evp-cfo-coo-palkhiwala-sells-457-129-in-qcom-stock",
        "published": "2026-09-11T23:45:50.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}